The suboptimal efficacy of CD47-targeting monotherapy can be attributed to multiple factors, including the complexity of the tumor microenvironments, cancer cell heterogeneity, immune system dysfunction and modulation, and off-target effects, but the utmost factor has been hematotoxicity, which ultimately set the upper limit of the therapeutic doses (15). This evidence concerns the gene CD47 and cancer.